ECSP10010291A - Derivados bicíclicos para usar en el tratamiento de afecciones asociadas con el receptor de andrógeno - Google Patents

Derivados bicíclicos para usar en el tratamiento de afecciones asociadas con el receptor de andrógeno

Info

Publication number
ECSP10010291A
ECSP10010291A EC2010010291A ECSP10010291A ECSP10010291A EC SP10010291 A ECSP10010291 A EC SP10010291A EC 2010010291 A EC2010010291 A EC 2010010291A EC SP10010291 A ECSP10010291 A EC SP10010291A EC SP10010291 A ECSP10010291 A EC SP10010291A
Authority
EC
Ecuador
Prior art keywords
treatment
bicyclic derivatives
androgen
affections
receiver
Prior art date
Application number
EC2010010291A
Other languages
English (en)
Inventor
Robert Hugh Bradbury
Neil James Hales
Alfred Arthur Rabow
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP10010291A publication Critical patent/ECSP10010291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a los compuestos bicíclicos de Fórmula (I), donde los números enteros X1, X2, X3, el Anillo A, R4, R5 y m son como los definidos en la descripción. La presente invención también se relaciona con procesos para la preparación de tales compuestos, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para su uso en la prevención o tratamiento de afecciones asociadas con el receptor de andrógeno.
EC2010010291A 2007-12-21 2010-06-21 Derivados bicíclicos para usar en el tratamiento de afecciones asociadas con el receptor de andrógeno ECSP10010291A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1575507P 2007-12-21 2007-12-21
US9609008P 2008-09-11 2008-09-11
US10780408P 2008-10-23 2008-10-23

Publications (1)

Publication Number Publication Date
ECSP10010291A true ECSP10010291A (es) 2010-07-30

Family

ID=40428336

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010291A ECSP10010291A (es) 2007-12-21 2010-06-21 Derivados bicíclicos para usar en el tratamiento de afecciones asociadas con el receptor de andrógeno

Country Status (23)

Country Link
US (1) US8003649B2 (es)
EP (1) EP2235010A1 (es)
JP (1) JP2011507824A (es)
KR (1) KR20100099742A (es)
CN (1) CN101952286A (es)
AR (1) AR069911A1 (es)
AU (1) AU2008339572B2 (es)
BR (1) BRPI0821676A2 (es)
CA (1) CA2709514A1 (es)
CL (1) CL2008003846A1 (es)
CO (1) CO6331441A2 (es)
CR (1) CR11524A (es)
DO (1) DOP2010000195A (es)
EA (1) EA017144B1 (es)
EC (1) ECSP10010291A (es)
IL (1) IL206284A0 (es)
NI (1) NI201000110A (es)
NZ (1) NZ586913A (es)
PE (1) PE20091157A1 (es)
TW (1) TW200927121A (es)
UY (1) UY31559A1 (es)
WO (1) WO2009081197A1 (es)
ZA (1) ZA201004227B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013791A2 (en) * 2006-07-24 2008-01-31 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
WO2009005675A1 (en) * 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
MX2011006682A (es) 2008-12-22 2011-07-13 Merck Patent Gmbh Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion.
CN102388048B (zh) 2009-02-10 2014-07-30 阿斯利康(瑞典)有限公司 三唑并[4，3-b]哒嗪衍生物及其用于前列腺癌的用途
SG175726A1 (en) * 2009-05-11 2011-12-29 Astrazeneca Ab [1,2,4] triazolo [4,3-b] pyridazines as ligands of the androgen receptor
US8450374B2 (en) * 2009-06-29 2013-05-28 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
EP2491034B1 (en) 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
ES2585806T3 (es) * 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
WO2011082271A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted triazolo-pyrimidine compounds
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
NZ603876A (en) 2010-05-13 2015-02-27 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
US9006450B2 (en) 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
US9422290B2 (en) * 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
ES2718550T3 (es) 2013-05-13 2019-07-02 Glaxosmithkline Llc Análogos de urea con puente sustituidos como moduladores de sirtuinas
AU2014279240A1 (en) * 2013-06-10 2016-01-07 Astellas Pharma Inc. Bicyclic nitrogen-containing aromatic heterocyclic amide compound
NO2719005T3 (es) 2014-07-28 2018-01-20
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3285764B1 (en) * 2015-03-31 2024-03-27 University of Vermont and State Agricultural College Triazolopyridazines for treating cryptosporidiosis
HRP20220642T1 (hr) 2016-03-10 2022-06-24 Janssen Pharmaceutica Nv Postupci za liječenje depresije uporabom antagonista receptora oreksina 2
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
RS63311B1 (sr) 2016-06-22 2022-07-29 Ellipses Pharma Ltd Ar+ metode lečenja raka dojke
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
ES2921020T3 (es) * 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
GB201716871D0 (en) * 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds
GB201806663D0 (en) * 2018-04-24 2018-06-06 Avexxin As 2-Oxothiazole compositions for treatment of fibrotic disease
SMT202400265T1 (it) 2018-11-14 2024-07-09 Janssen Pharmaceutica Nv Metodi di sintesi migliorati per realizzare composti eterociclici fusi come modulatori del recettore per l'oressina
US12521386B2 (en) * 2018-12-11 2026-01-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of the androgen receptor activity and/or expression and uses thereof
CN109942574B (zh) * 2019-01-11 2022-04-01 成都阿奇生物医药科技有限公司 天奇替尼及其制备方法和用途
EP4360632B1 (en) 2019-01-15 2025-10-29 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
WO2020163689A1 (en) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists
EP4010325A1 (en) 2019-08-07 2022-06-15 Janssen Pharmaceutica NV Improved synthetic methods of making (2h-1,2,3-triazol-2-yl)phenyl compounds as orexin receptor modulators
EP4023649A1 (en) * 2020-12-30 2022-07-06 Industrial Technology Research Institute Androgen receptor binding bifunctional molecules
US20240262832A1 (en) * 2021-04-30 2024-08-08 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators
AU2024376208A1 (en) * 2023-11-10 2026-04-30 Suven Life Sciences Limited Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)
CN121181498A (zh) * 2025-09-03 2025-12-23 遵义医科大学第五附属(珠海)医院 一种醚类芳基哌嗪衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL346795A1 (en) 1998-09-22 2002-02-25 Yamanouchi Pharma Co Ltd Cyanophenyl derivatives
US6184249B1 (en) 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
EP1796669B1 (en) 2004-10-01 2010-09-22 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2008109104A1 (en) * 2007-03-07 2008-09-12 The Regents Of The University Of California Bivalent inhibitors of akt protein kinase

Also Published As

Publication number Publication date
DOP2010000195A (es) 2010-08-31
WO2009081197A1 (en) 2009-07-02
EP2235010A1 (en) 2010-10-06
US20100016279A1 (en) 2010-01-21
TW200927121A (en) 2009-07-01
NZ586913A (en) 2012-06-29
CL2008003846A1 (es) 2010-02-05
UY31559A1 (es) 2009-08-03
ZA201004227B (en) 2011-10-26
AR069911A1 (es) 2010-03-03
KR20100099742A (ko) 2010-09-13
US8003649B2 (en) 2011-08-23
JP2011507824A (ja) 2011-03-10
AU2008339572B2 (en) 2012-05-10
BRPI0821676A2 (pt) 2015-06-16
EA201000946A1 (ru) 2010-12-30
NI201000110A (es) 2012-05-14
CO6331441A2 (es) 2011-10-20
CA2709514A1 (en) 2009-07-02
EA017144B1 (ru) 2012-10-30
CR11524A (es) 2010-08-05
PE20091157A1 (es) 2009-09-03
IL206284A0 (en) 2010-12-30
CN101952286A (zh) 2011-01-19
AU2008339572A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
NI201000110A (es) Derivados bicíclicos para usar en el tratamiento de afecciones asociadas con el receptor de andrógeno.
CR11801A (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
ECSP099620A (es) Derivados de ciclohexano espirociclico
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
UY32426A (es) Derivados bicilicos para uso en el tratamiento de enfermedades relacionadas al receptor de androgeno
ECSP11011517A (es) Compuestos antivirales
ECSP13012519A (es) Compuestos sustituidos de benzamida
CL2012001461A1 (es) Compuestos derivados de difenil-pirazolopiridinas, moduladores del receptor nuclear nurr-1; compuestos intermediarios; composición farmacéutica; y su uso para el tratamiento y prevención de enfermedades neurodegenerativas, traumatismos cerebrales, enfermedades inflamatorias, osteoporosis, cáncer, entre otras.
CL2011002103A1 (es) Compuestos derivados de indazol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica y combinacion que los comprende; y uso para tratar una afeccion para la que esta indicado un antagonista del receptor ccr4.
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
UY32623A (es) Derivados bicíclicos para afecciones asociadas al receptor de andrógenos
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
CL2012000351A1 (es) Compuestos derivados de azetidin-2-ona; con un efecto inhibidor sobre el colesterol; procedimiento para preparar los compuestos; compuestos intermediarios; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos.
CL2010001432A1 (es) Compuestos derivados de 2-oxo-alquil-1-piperazin-2-ona, afines por los receptores p75ntr; procedimiento para preparar los compuestos; compuesto intermediario; medicamento y composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas.
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
CU20100129A7 (es) Derivados bicíclicos para usar en el tratamiento de afecciones asociadas con el receptor de andrógeno
CU20100249A7 (es) Derivados de benzoxazinona que actúan como agonistas de receptores adrenérgcos beta2 para el tratamiento de trastornos respiratorios
CU20100226A7 (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo